aspartic acid has been researched along with Bone Cancer in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Chen, J; Chen, X; Gu, Y; Huang, S; Wang, H; Wu, X; Xu, Y; Zhang, H; Zhang, Y | 1 |
| Fukui, M; Katsumi, H; Kimura, H; Nakao, Y; Sakane, T; Shimizu, E; Yamamoto, A; Yamashita, S; Yoshioka, A | 1 |
| Hibino, N; Isobe, Y; Katsumi, H; Naito, C; Tanaka, Y; Yagi, Y; Yamada, S; Yamamoto, A; Yamashita, S | 1 |
| Kopeček, J; Low, SA; Yang, J | 1 |
| Costa, S; Ferreira, P; Lopes, C; Medeiros, RM; Morais, A; Oliveira, J; Pinto, D; Vasconcelos, A | 1 |
| Benjamin, RS; Bodey, GP; Kurzrock, R; Papdopoulos, N; Plager, C; Valdivieso, M; Yap, BS | 1 |
| Albor, A; El-Hizawi, S; Kulesz-Martin, M; Lagowski, JP | 1 |
| Ein, D; Glenner, GG; Terry, WD | 1 |
| Nieper, A | 1 |
1 review(s) available for aspartic acid and Bone Cancer
| Article | Year |
|---|---|
The immunoglobulin origin of amyloid.
Topics: Amino Acid Sequence; Amyloid; Amyloidosis; Antigen-Antibody Complex; Aspartic Acid; Bence Jones Protein; Bone Neoplasms; Cyclophosphamide; Fluorescent Antibody Technique; Humans; Immunoglobulins; Melphalan; Molecular Weight; Multiple Myeloma; Myeloma Proteins; Peptides; Plasma Cells; Polysaccharides; Ultracentrifugation | 1972 |
8 other study(ies) available for aspartic acid and Bone Cancer
| Article | Year |
|---|---|
Study on the cellular internalization mechanisms and
Topics: Animals; Arginine; Aspartic Acid; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Cysteine; Genetic Vectors; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Peptide Fragments; Peptide T; Polyethylene Glycols; Prostatic Neoplasms; Tumor Burden | 2020 |
Dendrimer-based micelles with highly potent targeting to sites of active bone turnover for the treatment of bone metastasis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aspartic Acid; Bone Neoplasms; Cell Line, Tumor; Cholesterol; Dendrimers; Drug Carriers; Drug Compounding; Female; Injections, Intravenous; Male; Melanoma, Experimental; Mice, Inbred C57BL; Micelles; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats, Wistar; Single Photon Emission Computed Tomography Computed Tomography; Tissue Distribution | 2020 |
Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis.
Topics: Animals; Apoptosis; Aspartic Acid; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Durapatite; Female; Flow Cytometry; Fluorescent Dyes; Liposomes; Male; Mice, Inbred C57BL; Osteoclasts; Paclitaxel; Polyethylene Glycols; Time Factors; Tissue Distribution; Tritium | 2018 |
Bone-targeted acid-sensitive doxorubicin conjugate micelles as potential osteosarcoma therapeutics.
Topics: Amino Acids; Aspartic Acid; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Liberation; Durapatite; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kinetics; Micelles; Oligopeptides; Osteosarcoma | 2014 |
Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7.
Topics: Aged; Aspartic Acid; Bone Neoplasms; Disease Progression; Exons; Genotype; Glutamic Acid; Humans; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Prognosis; Prostatic Neoplasms; Treatment Outcome | 2002 |
Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Bone Neoplasms; Diarrhea; Drug Evaluation; Female; Humans; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Sarcoma; Skin Diseases; Soft Tissue Neoplasms; Stomatitis | 1984 |
Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.
Topics: Aspartic Acid; Bone Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Enzyme Inhibitors; Gene Amplification; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mutation; Osteosarcoma; Phenotype; Phosphonoacetic Acid; Protein Structure, Tertiary; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Recalcification of bone metastases by calcium diorotate.
Topics: Adult; Aspartic Acid; Biological Transport, Active; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Calciphylaxis; Calcium; Decalcification, Pathologic; Female; Humans; Neoplasm Metastasis; Orotic Acid; Phosphoric Acids | 1970 |